These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 26788717)

  • 1. Systemic lupus erythematosus following rituximab treatment for non-Hodgkin lymphoma.
    Soura E; Avgerinou G; Papoutsaki M; Stavropoulos P; Antoniou C
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):298-301. PubMed ID: 26788717
    [No Abstract]   [Full Text] [Related]  

  • 2. New-onset psoriasis induced by rituximab therapy for non-Hodgkin lymphoma in a child.
    Kim DW; Park SK; Woo SH; Yun SK; Kim HU; Park J
    Eur J Dermatol; 2016 Apr; 26(2):190-1. PubMed ID: 26771919
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug-induced photodistributed rash.
    O'Connor R; Flynn A; Crowther S; Tobin AM; Connolly M
    Clin Exp Dermatol; 2017 Jul; 42(5):590-592. PubMed ID: 28548245
    [No Abstract]   [Full Text] [Related]  

  • 4. Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma.
    Chebib R; Ghorra C; Kattan J
    J Cancer Res Ther; 2015; 11(3):646. PubMed ID: 26458604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
    Mielke F; Schneider-Obermeyer J; Dörner T
    Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
    [No Abstract]   [Full Text] [Related]  

  • 6. [Intravitreal rituximab for the treatment of intraocular relapse of non-Hodgkin's lymphoma].
    Fernández Cañabate E; Fernández-Cañabate S
    Farm Hosp; 2018 Jan; 42(1):20-21. PubMed ID: 29306309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-Onset Neutropenia After Rituximab-Containing Therapy for Non-Hodgkin Lymphoma.
    Aguiar-Bujanda D; Blanco-Sánchez MJ; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura-Grau S; Bohn-Sarmiento U
    Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):761-5. PubMed ID: 26319620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced systemic lupus erythematosus in a child after 3 years of treatment with carbamazepine.
    Molina-Ruiz AM; Lasanta B; Barcia A; Pérez-Vega E; Requena L
    Australas J Dermatol; 2017 Feb; 58(1):e20-e22. PubMed ID: 26424435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for developing infusion reaction after rituximab administration in patients with B-cell non-Hodgkin's lymphoma.
    Tachi T; Yasuda M; Usui K; Umeda M; Nagaya K; Osawa T; Ichihashi A; Noguchi Y; Goto H; Kasahara S; Takahashi T; Goto C; Teramachi H
    Pharmazie; 2015 Oct; 70(10):674-7. PubMed ID: 26601425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
    Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
    J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Insidious drug eruption].
    Heikkilä H; Kariniemi AL
    Duodecim; 2001; 117(6):573-5. PubMed ID: 12116489
    [No Abstract]   [Full Text] [Related]  

  • 12. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manifestations and treatment of cutaneous lupus erythematosus (part I of II).
    Schairer D; Friedman A
    J Drugs Dermatol; 2011 Oct; 10(10):1212-4. PubMed ID: 21968677
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vaccination of patients with non-Hodgkin lymphoma under rituximab or other immunosuppressive drugs].
    Rodríguez-García J; Fernández-Santos R; García-Erce JA
    Med Clin (Barc); 2016 Jan; 146(1):43-4. PubMed ID: 25851912
    [No Abstract]   [Full Text] [Related]  

  • 15. Retroperitoneal fibrosis due to B-cell non-Hodgkin lymphoma: Responding to rituximab!
    Alvarez Argote J; Bauer FA; Posteraro AF; Dasanu CA
    J Oncol Pharm Pract; 2016 Feb; 22(1):179-85. PubMed ID: 25013186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fulminant hepatitis B as a result of reactivation in hematologic patient after rituximab therapy.
    Yilmaz B
    J Med Virol; 2016 Aug; 88(8):1289-90. PubMed ID: 27249067
    [No Abstract]   [Full Text] [Related]  

  • 17. A case of a focal oedematous reaction induced by rituximab overlying lupus erythematosus tumidus.
    Bohelay G; Rousset L; Levy A; Arana R; Laroche L; Caux F
    Eur J Dermatol; 2017 Oct; 27(5):542-543. PubMed ID: 28691689
    [No Abstract]   [Full Text] [Related]  

  • 18. Marked elevation of procalcitonin in a patient with a drug related infusion reaction to rituximab.
    Robier C; Neubauer M; Reicht G
    Clin Chem Lab Med; 2016 Mar; 54(3):e101-3. PubMed ID: 26389633
    [No Abstract]   [Full Text] [Related]  

  • 19. Inefficacy of rituximab in a case of low grade non-Hodgkin's lymphoma with cryoglobulinemia.
    Baronciani D; Angelucci E; Gaziev J; Visani G
    Haematologica; 2002 Jul; 87(7):ELT33. PubMed ID: 12091148
    [No Abstract]   [Full Text] [Related]  

  • 20. Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma.
    Gajra A; Vajpayee N; Grethlein SJ
    Am J Hematol; 2004 Oct; 77(2):196-7. PubMed ID: 15389902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.